Ankylosing spondylitis is a polygenic disease triggered by a combination of genetic and environmental factors. In the early stage of ankylosing spondylitis, it is mainly treated with non-steroidal anti-inflammatory drugs (NSAIDs), biological anti-rheumatic drugs (BARDs) and traditional anti-rheumatic drugs (ARDs) to improve the condition.
1. Non-steroidal anti-inflammatory drugs: common non-steroidal anti-inflammatory drugs include Loxoprofen, Meloxicam, Ibuprofen, etc. This kind of drugs can effectively relieve the symptoms of ankylosing spondylitis such as swollen joints and morning stiffness. During the use of these drugs, it is necessary to closely observe whether there are any adverse reactions in the digestive tract.
2. Bio-improving anti-rheumatic drugs: representative biosynthetic anti-rheumatic drugs include infliximab, etanercept, etc. These drugs have the ability to inhibit the bone destruction of ankylosing spondylitis and have better efficacy in peripheral and central axial symptoms as well as extra-articular manifestations, such as uveitis.
3. Traditional anti-rheumatic drugs to improve the condition: traditional synthetic anti-rheumatic drugs, including leflunomide, salazosulfapyridine, thalidomide, etc., can alleviate the clinical symptoms of patients with ankylosing spondylitis and reduce the effect of laboratory activity indicators.
The above drugs need to be used under the guidance of a physician, ankylosing spondylitis patients can go to the rheumatology and immunology department of a regular hospital and other related departments for detailed consultation, and follow the doctor’s instructions to use the drug.